Piperidine and azepine derivatives as prokineticin receptor modulators

1. A compound of formula

wherein

R 1 represents a C 5 -C 10 aryl group which is optionally substituted by at least one substituent independently selected from halogen, hydroxyl, cyano, oxo, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 alkylthio, C 1 -C 6 alkylsulphinyl, C 1 -C 6 alkylsulphonyl, C 1 -C 6 alkylcarbonyl, C 1 -C 6 alkylcarbonyloxy, C 1 -C 6 alkoxycarbonyl, —NR 6 R 7 , —CONR 8 R 9 , C 3 -C 6 cycloalkyl, C 3 -C 6 cycloalkyloxy or C 3 -C 6 cycloalkylmethyl;

R 2 represents a hydrogen or fluorine atom or a hydroxyl, C 1 -C 3 alkoxy or trifluoromethoxy group and R 3 represents a hydrogen atom, or R 2 and R 3 may together form a carbon-carbon bond;

X represents a group CHR 4 ;

R 4 represents a hydrogen atom or, when R 3 represents a hydrogen atom, R 4 may together with R 2 form a carbon-carbon bond;

m is 1 or 2;

R 5 represents a 5- to 6-membered heteroaryl group comprising a pyrindinyl group, a pyridazninyl group or a pyrazolyl group, the heteroaryl group being optionally substituted by at least one substituent independently selected from halogen, cyano, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 alkylsulphinyl, C 1 -C 6 alkylsulphonyl, C 1 -C 6 alkylcarbonyl, C 1 -C 6 alkylcarbonyloxy, C 1 -C 6 alkoxycarbonyl, —NR 10 R 11 , —CONR 12 R 13 , C 3 -C 6 cycloalkyl, C 3 -C 6 cycloalkyloxy or C 3 -C 6 cycloalkylmethyl;

R 6 and R 7 each independently represent a hydrogen atom or a C 1 -C 6 alkyl or C 3 -C 6 cycloalkyl group, or R 6 and R 7 may together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring optionally substituted by halogen or hydroxy;

R 8 and R 9 each independently represent a hydrogen atom or a C 1 -C 6 alkyl group, or R 8 and R 9 may together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring;

R 10 and R 11 each independently represent a hydrogen atom or a C 1 -C 6 alkyl or C 3 -C 6 cycloalkyl group, or R 10 and R 11 may together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring optionally substituted by halogen or hydroxy; and

R 12 and R 13 each independently represent a hydrogen atom or a C 1 -C 6 alkyl group, or R 12 and R 13 may together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring;

provided that the compound of formula (I) is not:

(3-(4-chlorophenyl)-1-piperidinyl)(1-methyl-3-propyl-1H-pyrazol-5-yl)methanone,

(6-amino-3-pyridinyl)(3-(2-methylphenyl)-1-piperidinyl)methanone,

(2-amino-4-pyridinyl)(3-(2-methylphenyl)-1-piperidinyl)methanone,

[1-ethyl-3-(1-methyethyl)-1H-pyrazol-5-yl][3-(2-methylphenyl)-1-piperidinyl]methanone,

[3-(3-methylphenyl)-1-piperidinyl](1-methyl-3-propyl-1H-pyrazol-5-yl)methanone,

[3-(3-methylphenyl)-1-piperidinyl]-2-pyridinyl-methanone,

5-[[3-(2-methylphenyl)-1-piperidinyl]carbonyl]-2-pyridinecarbonitrile,

(2-methoxy-3-pyridinyl)[3-(3-methylphenyl)-1-piperidinyl]methanone,

[3-(2-methylphenyl)-1-piperidinyl](3-propyl-1H-pyrazol-4-yl)methanone,

(1-ethyl-1H-pyrazol-4-yl)[3-(3-methylphenyl)-1-piperidinyl]methanone,

[1-(1-methylethyl)-1H-pyrazol-4-yl](3-phenyl-1-piperidinyl)methanone, or

[3-hydroxy-3-(2-methoxyphenyl)-1-piperidinyl][1-(1-methylethyl)-1H-pyrazol-5-yl]methanone;

or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 , wherein R 1 represents a C 5 -C 10 aryl group which is optionally substituted by at least one substituent independently selected from halogen, cyano, C 1 -C 2 alkyl, C 1 -C 2 haloalkyl, C 1 -C 2 alkoxy and C 1 -C 2 haloalkoxy.

3. A compound according to claim 1 , wherein, in R 1 , the aryl group is phenyl.

4. A compound according to claim 1 , wherein R 2 represents a hydrogen atom and R 3 represents a hydrogen atom.

5. A compound according to claim 1 , wherein m is 1.

6. A compound according to claim 1 , wherein R 4 represents a hydrogen atom.

7. A compound according to claim 1 , wherein R 5 represents a 5- to 6-membered heteroaryl group comprising a pyrindinyl group, a pyridazinyl group or a pyrazolyl group, the heteroaryl group being optionally substituted by at least one substituent independently selected from halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, —NR 10 R 11 or C 3 -C 6 cycloalkyl.

8. A compound according to claim 1 , wherein the R 5 heteroaryl group is selected from 4-pyridinyl, 4-pyridazinyl and 4-pyrazolyl.

9. A compound according to claim 1 , wherein R 10 and R 11 each independently represent a hydrogen atom or a C 1 -C 3 alkyl or cyclopropyl group.

10. A compound according to claim 9 , wherein R 10 and R 11 each represent a hydrogen atom when the R 5 heteroaryl group is 5-membered, or, wherein one of R 10 and R 11 represents a hydrogen atom and the other of R 10 and R 11 represents a C 1 -C 3 alkyl group when the R 5 heteroaryl group is 6-membered.

11. A compound being selected from:

4-{[3-(2-Fluorophenyl)piperidin-1-yl]carbonyl}-N,N-dimethylpyridin-2-amine,

4-{[3-(2,4-Dichlorophenyl)piperidin-1-yl]carbonyl}-N,N-dimethylpyridin-2-amine,

4-{[3-(4-Chlorophenyl)piperidin-1-yl]carbonyl}-2-cyclopropylpyridine,

4-{[3-(4-Chloro-2-methylphenyl)piperidin-1-yl]carbonyl}-2-ethylpyridine,

4-{[3-(4-Chloro-2-methylphenyl)piperidin-1-yl]carbonyl}-2-methylpyridine,

4-({3-[4-Chloro-2-(trifluoromethyl)phenyl]piperidin-1-yl}carbonyl)-2-ethylpyridine,

4-({3-[4-Chloro-2-(trifluoromethyl)phenyl]piperidin-1-yl}carbonyl)-N,N-dimethylpyridin-2-amine,

4-{[3-(4-Chlorophenyl)piperidin-1-yl]carbonyl}-N-(propan-2-yl)pyridin-2-amine,

4-({3-[4-Chloro-2-(trifluoromethyl)phenyl]piperidin-1-yl}carbonyl)-2-methoxypyridine,

4-({3-[4-Chloro-2-(trifluoromethyl)phenyl]piperidin-1-yl}carbonyl)-2-methylpyridine,

N-Methyl-4-{[3-(4-methylphenyl)piperidin-1-yl]carbonyl}pyridin-2-amine,

2-Methyl-4-{[3-(4-methylphenyl)piperidin-1-yl]carbonyl}pyridine,

N,N-Dimethyl-4-{[3-(3-methylphenyl)piperidin-1-yl]carbonyl}pyridin-2-amine,

N,N-Dimethyl-4-{[3-(2-methylphenyl)piperidin-1-yl]carbonyl}pyridin-2-amine,

N,N-Dimethyl-4-[(3-phenylpiperidin-1-yl)carbonyl]pyridin-2-amine,

4-{[3-(4-Chlorophenyl)piperidin-1-yl]carbonyl}-N,N-dimethylpyridin-2-amine,

4-{[(3 S)-3-(4-Chlorophenyl)piperidin-1-yl]carbonyl}-N,N-dimethylpyridin-2-amine,

4-{[(3R)-3-(4-Chlorophenyl)piperidin-1-yl]carbonyl}-N,N-dimethylpyridin-2-amine,

4-{[3-(4-Fluorophenyl)piperidin-1-yl]carbonyl}-N,N-dimethylpyridin-2-amine,

2-Ethyl-4-{[3-(4-methylphenyl)piperidin-1-yl]carbonyl}pyridine,

2-(Azetidin-1-yl)-4-{[3-(4-methylphenyl)piperidin-1-yl]carbonyl}pyridine,

2-(Azetidin-1-yl)-4-{[3-(4-chlorophenyl)piperidin-1-yl]carbonyl}pyridine,

2-(Azetidin-1-yl)-4-{[3-(2-methylphenyl)piperidin-1-yl]carbonyl}pyridine,

4-{[3-(4-Chloro-2-methylphenyl)piperidin-1-yl]carbonyl}-N,N-dimethylpyridin-2-amine,

4-{[3-(4-Chloro-2-fluorophenyl)piperidin-1-yl]carbonyl}-N,N-dimethylpyridin-2-amine,

4-{[3-(2-Chloro-4-fluorophenyl)piperidin-1-yl]carbonyl}-N,N-dimethylpyridin-2-amine,

4-{[3-(4-Chlorophenyl)piperidin-1-yl]carbonyl}-N-methylpyridin-2-amine,

4-{[3-(4-Chlorophenyl)piperidin-1-yl]carbonyl}-2,6-dimethylpyridine,

2-Chloro-4-{[3-(4-chlorophenyl)piperidin-1-yl]carbonyl}pyridine,

4-{[3-(4-Chlorophenyl)piperidin-1-yl]carbonyl}-2-(propan-2-yl)pyridine,

4-{[3-(4-Chloro-2-methylphenyl)piperidin-1-yl]carbonyl}-N-methylpyridin-2-amine,

4-{[3-(4-Chloro-2-methylphenyl)piperidin-1-yl]carbonyl}-2-methoxypyridine,

2-(Azetidin-1-yl)-4-{[3-(4-chloro-2-methylphenyl)piperidin-1-yl]carbonyl}pyridine,

2-Methoxy-4-{[3-(4-methylphenyl)piperidin-1-yl]carbonyl}pyridine,

4-{[3-(4-Methylphenyl)piperidin-1-yl]carbonyl}-2-(pyrrolidin-1-yl)pyridine,

4-{[(3S)-3-(3-Methoxyphenyl)piperidin-1-yl]carbonyl}-N,N-dimethylpyridin-2-amine,

N-Ethyl-N-methyl-4-{[3-(4-methylphenyl)piperidin-1-yl]carbonyl}pyridin-2-amine,

2-(3,3-Difluoroazetidin-1-yl)-4-{[3-(4-methylphenyl)piperidin-1-yl]carbonyl}pyridine,

N-Methyl-4-{[3-(4-methylphenyl)piperidin-1-yl]carbonyl}-N-propylpyridin-2-amine,

N-Methyl-4-{[3-(4-methylphenyl)piperidin-1-yl]carbonyl}-N-(propan-2-yl)pyridin-2-amine,

1-(4-{[3-(4-Methylphenyl)piperidin-1-yl]carbonyl}pyridin-2-yl)azetidin-3-ol,

4-{[3-(4-Chlorophenyl)piperidin-1-yl]carbonyl}-2-ethoxypyridine,

N-Cyclopropyl-N-methyl-4-{[3-(4-methylphenyl)piperidin-1-yl]carbonyl}pyridin-2-amine,

N,N-Dimethyl-4-({3-[4-(trifluoromethyl)phenyl]piperidin-1-yl}carbonyl)pyridin-2-amine,

N,N-Dimethyl-4-({3-[2-(trifluoromethyl)phenyl]piperidin-1-yl}carbonyl)pyridin-2-amine,

4-{[3-(2-Chlorophenyl)piperidin-1-yl]carbonyl}-N,N-dimethylpyridin-2-amine,

4-{[3-(4-Methoxyphenyl)piperidin-1-yl]carbonyl}-N,N-dimethylpyridin-2-amine,

4-{[3-(2-Methoxyphenyl)piperidin-1-yl]carbonyl}-N,N-dimethylpyridin-2-amine,

N,N-Dimethyl-4-{[3-(4-methylphenyl)piperidin-1-yl]carbonyl}pyridin-2-amine,

N,N-Dimethyl-4-{[3-(4-methylphenyl)piperidin-1-yl]carbonyl}pyridin-2-amine (R Enantiomer),

N,N-Dimethyl-4-{[3-(4-methylphenyl)piperidin-1-yl]carbonyl}pyridin-2-amine (S Enantiomer),

4-{[3-(4-Chlorophenyl)piperidin-1-yl]carbonyl}-2-ethylpyridine,

N-Methyl-4-({3-[4-(trifluoromethyl)phenyl]piperidin-1-yl}carbonyl)pyridin-2-amine,

N-Methyl-4-({3-[2-(trifluoromethyl)phenyl]piperidin-1-yl}carbonyl)pyridin-2-amine,

4-{[3-(4-Methoxyphenyl)piperidin-1-yl]carbonyl}-N-methylpyridin-2-amine,

4-{[3-(2-Methoxyphenyl)piperidin-1-yl]carbonyl}-N-methylpyridin-2-amine,

4-({3-[4-Chloro-2-(trifluoromethyl)phenyl]piperidin-1-yl}carbonyl)-N-methylpyridin-2-amine,

2-Ethyl-4-({3-[2-(trifluoromethyl)phenyl]piperidin-1-yl}carbonyl)pyridine,

2-Ethyl-4-{[3-(2-methoxyphenyl)piperidin-1-yl]carbonyl}pyridine,

N,N-Dimethyl-4-({3-[2-(trifluoromethoxy)phenyl]piperidin-1-yl}carbonyl)pyridin-2-amine,

4-{[3-(4-Chloro-2-ethoxyphenyl)piperidin-1-yl]carbonyl}-N,N-dimethylpyridin-2-amine,

4-({3-[4-Methoxy-2-(trifluoromethyl)phenyl]piperidin-1-yl}carbonyl)-N,N-dimethylpyridin-2-amine,

4-{[3-(4-Methoxy-2-methylphenyl)piperidin-1-yl]carbonyl}-N-methylpyridin-2-amine,

4-({3-[4-Methoxy-2-(trifluoromethyl)phenyl]piperidin-1-yl}carbonyl)-N-methylpyridin-2-amine,

4-{[3-(4-Chloro-2-ethoxyphenyl)piperidin-1-yl]carbonyl}-N-methylpyridin-2-amine,

4-({3-[2-(Difluoromethoxy)phenyl]piperidin-1-yl}carbonyl)-N,N-dimethylpyridin-2-amine,

2-(1-{[2-(Dimethylamino)pyridin-4-yl]carbonyl}piperidin-3-yl)benzonitrile,

4-{[3-(4-Chloro-2,6-dimethylphenyl)piperidin-1-yl]carbonyl}-N,N-dimethylpyridin-2-amine,

5-{[3-(4-Chlorophenyl)piperidin-1-yl]carbonyl}-N,N-dimethylpyridazin-3-amine,

5-{[3-(4-Chloro-2-methylphenyl)piperidin-1-yl]carbonyl}-N,N-dimethylpyridazin-3-amine,

5-{[3-(4-Chloro-2-methylphenyl)piperidin-1-yl]carbonyl}-N-methylpyridazin-3-amine,

5-{[(3R)-3-(4-Chloro-2-methylphenyl)piperidin-1-yl]carbonyl}-N-methylpyridazin-3-amine,

5-{[(3S)-3-(4-Chloro-2-methylphenyl)piperidin-1-yl]carbonyl}-N-methylpyridazin-3-amine,

5-{[3-(4-Chloro-2-methylphenyl)piperidin-1-yl]carbonyl}-3-methoxypyridazine,

5-({3-[4-Chloro-2-(trifluoromethyl)phenyl]piperidin-1-yl}carbonyl)-N,N-dimethylpyridazin-3-amine,

5-({3-[4-Chloro-2-(trifluoromethyl)phenyl]piperidin-1-yl}carbonyl)-N-methylpyridazin-3-amine,

3-(Azetidin-1-yl)-5-({3-[4-chloro-2-(trifluoromethyl)phenyl]piperidin-1-yl}carbonyl)pyridazine,

5-({3-[2-Methoxy-4-(trifluoromethyl)phenyl]piperidin-1-yl}carbonyl)-N-methylpyridazin-3-amine,

5-{[3-(4-Methoxy-2-methylphenyl)piperidin-1-yl]carbonyl}-N-methylpyridazin-3-amine,

5-{[3-(4-Methoxy-2-methylphenyl)piperidin-1-yl]carbonyl}-N,N-dimethylpyridazin-3-amine,

5-({3-[4-Methoxy-2-(trifluoromethyl)phenyl]piperidin-1-yl}carbonyl)-N-methylpyridazin-3-amine,

5-({3-[4-Methoxy-2-(trifluoromethyl)phenyl]piperidin-1-yl}carbonyl)-N,N-dimethylpyridazin-3-amine,

5-{[3-(4-Chloro-2-ethoxyphenyl)piperidin-1-yl]carbonyl}-N-methylpyridazin-3-amine,

5-{[3-(4-Chloro-2-ethoxyphenyl)piperidin-1-yl]carbonyl}-N,N-dimethylpyridazin-3-amine,

5-{[3-(4-Chloro-2-methylphenyl)piperidin-1-yl]carbonyl}-3-methylpyridazine,

5-{[3-(2-Methoxyphenyl)piperidin-1-yl]carbonyl}-N-methylpyridazin-3-amine,

3-(4-Chloro-2-methylphenyl)-1-[(1,3-dimethyl-1H-pyrazol-4-yl)carbonyl]piperidine,

3-(4-Chlorophenyl)-1-[(1,3-dimethyl-1H-pyrazol-4-yl)carbonyl]piperidine,

3-(4-Chlorophenyl)-1-[(1-methyl-1H-pyrazol-4-yl)carbonyl]piperidine,

3-(4-Chlorophenyl)-1-[(1-ethyl-1H-pyrazol-4-yl)carbonyl]piperidine,

3-(4-Chlorophenyl)-1-{[1-(propan-2-yl)-1H-pyrazol-4-yl]carbonyl}piperidine,

3-(4-Chloro-2-methylphenyl)-1-[(1-ethyl-1H-pyrazol-4-yl)carbonyl]piperidine,

3-(4-Chloro-2-methylphenyl)-1-{[1-(propan-2-yl)-1H-pyrazol-4-yl]carbonyl}piperidine,

3-(4-Chloro-2-methylphenyl)-1-[(1-methyl-1H-pyrazol-4-yl)carbonyl]piperidine,

4-{[3-(4-Chloro-2-methylphenyl)piperidin-1-yl]carbonyl}-1-methyl-1H-pyrazol-5-amine,

3-[4-Chloro-2-(trifluoromethyl)phenyl]-1-[(1H-pyrazol-4-yl)carbonyl]piperidine,

3-[4-Chloro-2-(trifluoromethyl)phenyl]-1-[(1-methyl-1H-pyrazol-4-yl)carbonyl]piperidine,

3-[4-Chloro-2-(trifluoromethyl)phenyl]-1-[(1-ethyl-1H-pyrazol-4-yl)carbonyl]piperidine,

3-[4-Chloro-2-(trifluoromethyl)phenyl]-1-{[1-(propan-2-yl)-1H-pyrazol-4-yl]carbonyl}piperidine,

4-({3-[4-Chloro-2-(trifluoromethyl)phenyl]piperidin-1-yl}carbonyl)-1-methyl-1H-pyrazol-3-amine,

1-[(1,3-Dimethyl-1H-pyrazol-4-yl)carbonyl]-3-(4-methoxy-2-methylphenyl)piperidine,

4-{[3-(4-Methoxy-2-methylphenyl)piperidin-1-yl]carbonyl}-1-methyl-1H-pyrazol-3-amine,

3-[4-Chloro-2-(trifluoromethyl)phenyl]-1-[(1,3-dimethyl-1H-pyrazol-4-yl)carbonyl]piperidine,

4-{[5-(4-Chlorophenyl)-1,2,3,4-tetrahydropyridin-1-yl]carbonyl}-N,N-dimethylpyridin-2-amine,

4-{[5-(4-Chloro-2-methylphenyl)-1,2,3,4-tetrahydropyridin-1-yl]carbonyl}-N,N-dimethylpyridin-2-amine,

4-{[5-(2,4-Dichlorophenyl)-1,2,3,4-tetrahydropyridin-1-yl]carbonyl}-N,N-dimethylpyridin-2-amine,

N,N-Dimethyl-4-[(3-phenylazepan-1-yl)carbonyl]pyridin-2-amine,

4-{[3-(4-Chlorophenyl)azepan-1-yl]carbonyl}-N,N-dimethylpyridin-2-amine,

4-{[3-(4-Methoxyphenyl)azepan-1-yl]carbonyl}-N,N-dimethylpyridin-2-amine,

4-{[3-(4-Methoxyphenyl)azepan-1-yl]carbonyl}-N-methylpyridin-2-amine,

4-{[3-(4-Chlorophenyl)azepan-1-yl]carbonyl}-N-methylpyridin-2-amine,

5-{[3-(4-Methoxyphenyl)azepan-1-yl]carbonyl}-N-methylpyridazin-3-amine,

5-{[3-(4-Chlorophenyl)azepan-1-yl]carbonyl}-N-methylpyridazin-3-amine,

5-{[3-(4-Methoxyphenyl)azepan-1-yl]carbonyl}-N,N-dimethylpyridazin-3-amine,

5-{[3-(4-Chlorophenyl)azepan-1-yl]carbonyl}-N,N-dimethylpyridazin-3-amine,

3-(4-Chloro-2-methylphenyl)-1-{[2-(dimethylamino)pyridin-4-yl]carbonyl}piperidin-3-ol,

1-{[2-(Dimethylamino)pyridin-4-yl]carbonyl}-3-(4-fluorophenyl)piperidin-3-ol,

4-({3-[4-Chloro-2-(trifluoromethyl)phenyl]piperidin-1-yl}carbonyl)-1-methyl-1H-pyrazol-3-amine (R Enantiomer),

4-({3-[4-Chloro-2-(trifluoromethyl)phenyl]piperidin-1-yl}carbonyl)-1-methyl-1H-pyrazol-3-amine (S Enantiomer),

and pharmaceutically acceptable salts thereof.

12. A process for the preparation of a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt thereof which comprises

(i) reacting a compound of formula

wherein m, X, R 1 , R 2 and R 3 are as defined in formula (I) or a salt thereof, with a compound of formula

wherein R 5 is as defined in formula (I); or

(ii) hydrogenating a compound of formula

or a mixture thereof, in which m, R 1 and R 5 are as defined in formula (I);

and optionally thereafter carrying out one or more of the following procedures:

removing any protecting groups

converting a compound of formula (I) into another compound of formula (I)

forming a pharmaceutically acceptable salt.

13. A pharmaceutical composition comprising a compound according to claim 1 in association with a pharmaceutically acceptable adjuvant, diluent or carrier, and optionally one or more other therapeutic agents.

14. A method for the treatment of schizophrenia, comprising administering to a patient in need thereof, a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

15. A method for the treatment of dementia or impaired learning, comprising administering to a patient in need thereof, a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

16. A method for the treatment of pain, comprising administering to a patient in need thereof, a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

17. A compound according to claim 1 , wherein the compound comprises a racemic mixture of 5-{[3-(4-Chloro-2-methylphenyl)piperidin-1-yl]carbonyl}-N-methylpyridazin-3-amine or a pharmaceutically acceptable salt thereof.

18. A compound comprising a mixture of the R and S enantiomers of 5-{[3-(4-Chloro-2-methylphenyl)piperidin-1-yl]carbonyl}-N-methylpyridazin-3-amine or pharmaceutically acceptable salts thereof.

19. A compound according to claim 1 , wherein the compound comprises 5-{[(3R)-3-(4-Chloro-2-methylphenyl)piperidin-1-yl]carbonyl}-N-methylpyridazin-3-amine or a pharmaceutically acceptable salt thereof.

20. A compound according to claim 1 , wherein the compound comprises a racemic mixture of 4-({3- [4-Chloro-2-(trifluoromethyl)phenyl]piperidin-1-yl}carbonyl)-1-methyl-1H-pyrazol-3-amine or a pharmaceutically acceptable salt thereof.

21. A compound comprising a mixture of the R and S enantiomers of 4-({3[4-Chloro-2-(trifluoromethyl)phenyl]piperidin-1-yl}carbonyl)-1-methyl-1H-pyrazol-3-amine or pharmaceutically acceptable salts thereof.

22. A compound according to claim 1 , wherein the compound comprises 4-({(3R)-3-[4-Chloro-2-(trifluoromethyl)phenyl]piperidin-1-yl}carbonyl)-1-methyl-1H-pyrazol-3-amine or a pharmaceutically acceptable salt thereof.

23. A compound according to claim 1 , wherein the compound comprises 4-({(3S)-3-[4-Chloro-2-(trifluoromethyl)phenyl]piperidin-1-yl}carbonyl)-1-methyl-1H-pyrazol-3-amine or a pharmaceutically acceptable salt thereof.